Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | DPYD | Q12882 | 4/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11614897 | 0.82 | ATAD2 (0.50) | ALDH1A1DPYDLMNAKMT2APOLB | |
| SCHEMBL7712458 | 0.82 | MEN1 (0.47) | ALDH1A1CYP1A2DPYDLMNAKMT2A | |
| SCHEMBL31090687 | 0.82 | DPYD (0.50) | ALDH1A1DPYDLMNAKMT2AMEN1 | |
| SCHEMBL3129822 | 0.80 | LYN (0.50) | ALDH1A1CYP1A2LMNAKMT2AGAA | |
| SCHEMBL11616692 | 0.78 | SLC6A4 (0.39) | ALDH1A1DPYDLMNAATAD2 | |
| SCHEMBL11617240 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CYP1A2DPYDBRD4LMNA | |
| SCHEMBL11287388 | 0.73 | BRD4 (0.43) | BRD4LMNAKMT2AGAA | |
| SCHEMBL8519375 | 0.71 | ATAD2 (0.46) | ALDH1A1LMNAMAPTATAD2 | |
| SCHEMBL1061623 | 0.71 | GAA (0.48) | ALDH1A1CYP1A2DPYDLMNAMAPT | |
| SCHEMBL102177 | 0.70 | ATAD2 (0.52) | ALDH1A1DPYDLMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2044054-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| WO-2008000692-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-4080454-A | 5-M-Tolyloxyuracil, anti-ulcer agent | PFIZER INC. (US) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | ALDH1A1 2667/4885CYP1A2 979/4885DPYD 417/4885 |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | SSTR5, SSTR3, NPY5R | ALDH1A1 2667/4885CYP1A2 979/4885DPYD 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.